All Serina Therapeutics, Inc. Articles
Serina Therapeutics (NYSE: SER) Secures JuvVentures (UK) Limited Equity Premium Financing To Advance Parkinson’s Disease Trials
Serina Therapeutics (NYSE: SER, $4.91) has secured the second $5 million tranche of a $10 million equity financing deal, strengthening its financial position as it prepares to advance its lead Parkinson's disease candidate, SER-252, into Phase 1 clinical trials in late 2025. In a financial maneuver ...
Feb 03, 2025
View Article
Stay Informed. Stay Competitive.
Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.
We value your privacy and will never share your information.
